Abstract: A sterilizable particle-size reduction apparatus, component parts thereof and a method of sterilizing and validating sterility thereof are provided. Also provided is use thereof to prepare sterile suspensions of drugs.

Abstract: A sterile composition of a pharmaceutical compound is prepared by combining solvent with a non-sterile pharmaceutical compound to form a solution and filtering to yield a sterile pharmaceutical compound, optionally removing all or part of the solvent, and under sterile conditions combining the compound with a pharmaceutically acceptable carrier.

Abstract: The present invention provides a process for handling ?9-THC, which comprises preparing a solution of ?9-THC in a solvent which exists as a gas at room temperature and atmospheric pressure. The invention also provides solutions of ?9-THC in the solvent and solid preparations of ?9-THC.

Abstract: A pharmaceutical composition containing a prostaglandin and an alkanoic acid ester of a polyethoxylated sorbitol in an amount effective to enhance the chemical stability of the prostaglandin, and the use thereof for treating ophthalmic conditions. Also disclosed are methods for enhancing the chemical stability of a prostaglandin-containing composition by using an alkanoic acid ester of a polyethoxylated sorbitol.

Abstract: A sterilizable particle-size reduction apparatus, component parts thereof and a method of sterilizing and validating sterility thereof are provided. Also provided is use thereof to prepare sterile suspensions of drugs.

Abstract: A compound of formula (I) wherein R is selected from (i) a 5 to 7 membered heterocyclic ring containing 1 to 3 heteroatoms independently selected from nitrogen, oxygen and sulfur, which is optionally substituted by one or more groups independently selected from halo, CN, NO2, (C1-C6)alkyl, (C1-C6)alkoxy and phenyl; (ii) (C1-C6)alkyl, which is optionally substituted by one or more substituents each independently selected from halo, oxo, CN, NO2, (C1-C6)alkyl, (C1-C6)alkoxy and phenyl; (iii) (C1-C6)alkyl substituted by (C3-C13)cycloalkyl, which is optionally substituted by one or more substituents each independently selected from halo, oxo, CN, NO2, (C1-C6)alkyl, (C1-C6)alkoxy and phenyl; and (iv) (C3-C13)cycloalkyl, which is optionally substituted by one or more substituents each independently selected from halo, oxo, CN, NO2, (C1-C6)alkyl, (C1-C6)alkoxy and phenyl.

Abstract: A process for the syntheses of 17?-hydroxy-7?-methyl-19-nor-17?-pregn-5(10)-ene-20-yne-3-one (tibolone, 11) and intermediates useful for the synthesis thereof.

Abstract: A sterilisable particle-size reduction apparatus, component parts thereof and a method of sterilising and validating sterility thereof are provided. Also provided is use thereof to prepare sterile suspensions of drugs.

Abstract: A sterilisable particle-size reduction apparatus, component parts thereof and a method of sterilising and validating sterility thereof are provided. Also provided is use thereof to prepare sterile suspensions of drugs.

Abstract: A sterile composition of a pharmaceutical compound is prepared by combining solvent with a non-sterile pharmaceutical compound to form a solution and filtering to yield a sterile pharmaceutical compound, optionally removing all or part of the solvent, and under sterile conditions combining the compound with a pharmaceutically acceptable carrier.

Abstract: A sterilisable particle-size reduction apparatus, component parts thereof and a method of sterilising and validating sterility thereof are provided. Also provided is use thereof to prepare sterile suspensions of drugs.

Abstract: The present invention provides a process for handling ?9-THC, which comprises preparing a solution of ?9-THC in a solvent which exists as a gas at room temperature and atmospheric pressure. The invention also provides solutions of ?9-THC in the solvent and solid preparations of ?9-THC.

Abstract: A sterilisable particle-size reduction apparatus, component parts thereof and a method of sterilising and validating sterility thereof are provided. Also provided is use thereof to prepare sterile suspensions of drugs.

Abstract: A sterilisable particle-size reduction apparatus, component parts thereof and a method of sterilising and validating sterility thereof are provided. Also provided is use thereof to prepare sterile suspensions of drugs.

Abstract: A sterilisable particle-size reduction apparatus, component parts thereof and a method of sterilizing and validating sterility thereof are provided. Also provided is use thereof to prepare sterile suspensions of drugs.

Abstract: The present invention provides isolated, purified ?9 THC. In another embodiment, the invention provides pharmaceutical compositions comprising isolated, purified ?9 THC and a pharmaceutically acceptable carrier. In another embodiment, the invention provides methods of preparing pharmaceutical compositions comprising isolated, purified ?9 THC and a pharmaceutically acceptable carrier.

Abstract: ?9 THC acid is obtained from plant material and extracted into an aqueous solvent under conditions of pH control. The acid is converted to a salt and the salt extracted into a polar solvent, yielding acid of high purity. The ?9 THC acid is then converted to ?9 THC which is further purified and combined with a carrier for pharmaceutical use.

Abstract: ?9 THC acid is obtained from plant material and extracted into an aqueous solvent under conditions of pH control. The acid is converted to a salt and the salt extracted into a polar solvent, yielding acid of high purity. The ?9 THC acid is then converted to ?9 THC which is further purified and combined with a carrier for pharmaceutical use.

Abstract: Disclosed are processes for the synthesis and purification of prostaglandins and analogues thereof, especially analogues of PGF2?.

Abstract: Disclosed are processes for the synthesis and purification of prostaglandins and analogues thereof, especially analogues of PGF2?.